Curo You

What it takes to spin up a peptide brand in under 3 months in 2026: one person @BadTechBandit (up to a week ago, building a tam now) and the best available AI models! Regulatory & supplier research, lab testing, and a fully custom Next.js (thank you @vercel) store instead of a 2015 looking WordPress template 😬. Every store agent wired straight into the app and backend for ads, social, inventory, order ops, sales analytics and on and on. Ops run through Hermes agent by @NousResearch with separate agents owning different parts of the business. At API rates the last 30 days of tokens would've cost ~$11.8K. Conservatively $75K+ saved vs hiring it out, 3PL and fulfillment included. Why custom? Because isn't a store with some AI bolted on. It was built agent-first from day one. Operations, marketing, logistics, all of it designed to run on agents with a human setting direction... Thank you @OpenAI @AnthropicAI @Teknium and many others! The one thing that stays human is our ustomer support! When you email us, a real person answers. Everything else, the ai all the way!

TL;DR: @HHSGov & @FDA will not take enforcement action against licensed pharmacies, federal facilities, or physicians that compound six peptides, as long as they meet strict conditions. This is a temporary policy that lasts while FDA decides through rulemaking whether to add these peptides to the official 503A bulks list. Compounded drugs are still not FDA-approved. Which ones "passed" None has been formally approved or added to the 503A list. These six are covered by the interim policy, and each is limited to certain routes: Peptide Allowed routes - BPC-157 (acetate) Subcutaneous, intramuscular, oral, topical - TB-500 (acetate) Subcutaneous or intramuscular injection - Epitalon (acetate) Subcutaneous or intramuscular injection, intermittent courses only - MOTS-c (acetate) Subcutaneous or intramuscular injection Semax (free base) Intranasal only KPV (acetate) Topical and oral only (no injection) For all six, FDA's drug review center (CDER) recommended against listing them. The advisory committee (PCAC) voted in favor. HHS sided with the committee, citing three things: new lot-level testing certificates from FDA-registered manufacturers, documented history of use, and its view that the safety concerns are theoretical rather than based on observed harm. Key conditions - Supply: The API must come from an FDA-registered manufacturer that follows good manufacturing practice (CGMP). Each lot needs a full certificate of analysis covering identity, purity, endotoxin, microbial and impurity testing. - One peptide per product: Blends aren't allowed. - Prescription: Each product needs a valid patient-specific prescription. - Reporting: Serious adverse events and quality problems must be reported to FDA's MedWatch. - Label: It must say "This is a compounded drug product. Not for resale." - Oral forms: The compounder must document that the formulation is adequately absorbed when taken by mouth. - Devices: Only an FDA 510(k)-cleared syringe may be packaged with the drug. HHS says it may revisit the policy if a safety or quality problem comes up. hhs.gov/sites/default/files/…

Peptide news: FDA's peptide compounding policy just cleared White House review. It's an interim notice, not a final rule. FDA still has to publish the text, and the list of covered peptides isn't public yet. Next step: the Federal Register. We'll post when it drops. teapawt.net/himshouse/status/21154…

"Consistent with Change" means the text was edited in White House review. The record doesn't say what changed. OIRA's review of FDA's peptide notice (RIN 0910-ZD94) reportedly concluded Oct 27 with that label. The text and any peptide list aren't public yet.

Tesamorelin is a 44-amino-acid peptide that signals the pituitary to release growth hormone in pulses. In a 2007 trial of 412 adults with HIV, visceral fat fell 15.2% on average over 26 weeks with tesamorelin and rose 5.0% with placebo. Sources: Falutz 2007; EGRIFTA WR label.

MOTS-c is a 16-amino-acid peptide coded in mitochondrial DNA, first reported in 2015. In 10 young men, one bike session raised muscle MOTS-c 11.9-fold. No known trial gives MOTS-c itself to people. Sources: Lee 2015; Reynolds 2021.

Reta is one peptide built to activate three receptors: GIP, GLP-1 and glucagon. In the phase 3 TRIUMPH-1 trial (2,339 adults, 80 weeks), the average weight change at the highest dose was -25.0%, against -3.9% on placebo. Sources: Jastreboff 2023; Jastreboff 2026.

TB-500 copies 7 amino acids from thymosin beta-4, a 43-amino-acid protein that holds spare actin. Most of the research is on the full protein. A phase 3 trial of thymosin beta-4 eye drops in 700 patients missed its main goals. Sources: Low 1981; Malinda 1999; NCT03937882.

GHK-Cu was found in human blood in 1973, in a study comparing plasma from young and older adults. It is a three-amino-acid chain that holds one copper ion. Human research is mostly small skin studies. Sources: Pickart & Thaler 1973; Badenhorst 2016.

BPC-157 is a 15-amino-acid piece of a peptide found in human gastric juice in the early 1990s. 30+ years of lab and animal research followed. Human data is still small. A placebo-controlled pilot is planned for 2027. Sources: Sikirić 1993; Vasireddi 2025; NCT07803250.

Epitalon, or AEDG, sits inside a narrow research record spanning telomerase and telomere measurements in cultured cells, lifespan experiments in fruit flies, and animal biological-timing observations. The recurring theme is cell timing, studied mostly outside humans.

KPV is the Lys-Pro-Val end fragment of alpha-MSH. Researchers study how PepT1 moves this short sequence into intestinal cells and how signaling changes in laboratory models. The evidence map includes cell work, mouse colitis models, and antimicrobial experiments.

MOTS-C is a mitochondrial-encoded stress signal. Researchers study how it can move toward the nucleus and interact with AMPK-related pathways when cells face metabolic demand. The evidence map spans cell work, mouse models, and endogenous human exercise observations.

Retatrutide is an investigational agonist designed around GLP-1, GIP, and glucagon receptors. Researchers are studying how those three signals work together across body-weight, glucose, and liver-fat endpoints. Human trials are active, and the molecule remains investigational.

PT-141, also called bremelanotide, is a melanocortin receptor agonist. Researchers study how receptors including MC4R relay signals through central nervous-system pathways involved in sexual response. Bremelanotide adds a specific human-trial and FDA-label context.

Thymosin alpha-1 research is about immune coordination. Dendritic cells, toll-like receptors, and T cells form a signaling network. Researchers study how that network changes across distinct immune settings, including HBV and sepsis programs.

AOD-9604 is a small hGH fragment studied for fat-cell signaling. Researchers have examined whether it can influence lipid handling through pathways separate from the classic growth-hormone receptor. The record spans rodent models and mixed human obesity trials.

Ipamorelin research follows a ghrelin-receptor signal into pituitary cells. That signal raises calcium inside somatotroph cells, which can release stored growth hormone. The research map includes pituitary signaling, animal gut-motility models, and early human PK/PD work.

CJC-1295 research is about sustained pituitary signaling. The DAC form binds albumin, extending how long the signal remains in circulation while growth-hormone pulses remain part of the measured pattern. The evidence includes animal work and small human studies.

Selank research centers on neural modulation. Scientists study GABA-related messages, enzymes that break down enkephalins, and how small shifts in those systems may change wider signaling patterns. The evidence map spans laboratory, animal, and small human studies.

Semax research starts with brain-cell signaling. Rodent studies examine BDNF, TrkB, and changes in gene activity, while small human studies add an early imaging layer. The recurring question is how an ACTH fragment may influence the way neural systems adapt and communicate.